Quotient Sciences, the Nottinghamshire headquartered drug development services organisation, has acquired Pharmaterials, a contract development and manufacturing organization (CDMO) based in Reading.
The deal follows the acquisitions of SeaView Research and QS Pharma in February 2017.
Pharmaterials has a significant track record in supporting the development of small molecule drug products for oral and inhaled delivery. The business was founded in 2000 and is located in a 48,000 sq ft facility.
Mark Egerton, Chief Executive, Quotient Sciences, said: “The acquisition of Pharmaterials strengthens Quotient’s service portfolio from preclinical formulation development through to commercial manufacturing. The addition expands Quotient’s global CDMO services with added capacity and capabilities to better serve our clients’ needs.”